0001209191-23-028507.txt : 20230510
0001209191-23-028507.hdr.sgml : 20230510
20230510165346
ACCESSION NUMBER: 0001209191-23-028507
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20221109
FILED AS OF DATE: 20230510
DATE AS OF CHANGE: 20230510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shawver Laura
CENTRAL INDEX KEY: 0001551891
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39756
FILM NUMBER: 23907395
MAIL ADDRESS:
STREET 1: 1255 CRESCENT GREEN DRIVE, SUITE 250
CITY: CARY
STATE: NC
ZIP: 27518
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARS Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001671858
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811489190
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-771-9307
MAIL ADDRESS:
STREET 1: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Silverback Therapeutics, Inc.
DATE OF NAME CHANGE: 20160412
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2022-11-09
0
0001671858
ARS Pharmaceuticals, Inc.
SPRY
0001551891
Shawver Laura
C/O ARS PHARMACEUTICALS, INC.
11682 EL CAMINO REAL, SUITE 120
SAN DIEGO
CA
92130
1
0
0
0
1
Common Stock
2022-11-09
4
S
0
43896
4.58
D
210346
D
Common Stock
2023-05-08
4
M
0
57100
1.27
A
267446
D
Common Stock
2023-05-08
4
S
0
57100
6.16
D
210346
D
Common Stock
2023-05-09
4
M
0
42900
1.27
A
253246
D
Common Stock
2023-05-09
4
S
0
42900
5.31
D
210346
D
Stock Option (Right to Buy)
1.27
2023-05-08
4
M
0
57100
0.00
D
2030-04-28
Common Stock
57100
345897
D
Stock Option (Right to Buy)
1.27
2023-05-09
4
M
0
42900
0.00
D
2030-04-28
Common Stock
42900
302997
D
Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.53 to $5.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $6.00 to $6.44, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.00 to $5.92, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
Immediately exercisable.
/s/ Kathleen Scott, Attorney-in-Fact
2023-05-10
EX-24
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY
FOR SECTION 16(a) FILINGS
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Richard Lowenthal, Kathleen Scott and Justin Chakma, signing
individually, as the undersigned's true and lawful attorney-in fact to:
(1) Execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director and/or stockholder of ARS Pharmaceuticals, Inc. (the
"Company"), Forms 3, 4, and 5 and amendments thereto in accordance with Section
16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")
and the rules thereunder;
(2) Do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
or amendment thereto and timely file such form with the United States Securities
and Exchange Commission (the "SEC") and any stock exchange or similar authority;
and
(3) Take any other action of any type whatsoever which, in the opinion of any
such attorney-in-fact, may be necessary or desirable in connection with the
foregoing authority, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of
Attorney shall be in such form and shall contain such terms and conditions as
such attorney-in-fact may approve in such attorney-in-facts discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever required,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Limited Power of Attorney and the rights and powers
herein granted. The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Limited Power of Attorney shall remain in full force and effect until the
earlier to occur of (a) undersigned is no longer required to file Forms 3, 4 and
5 with respect to any securities issued by the Company, (b) revocation by the
undersigned in a signed writing delivered to the foregoing attorney-in-fact and
(c) as to any attorney in fact individually until such attorney-in-fact is no
longer employed by the Company. This Limited Power of Attorney may be filed
with the SEC as a confirming statement of the authority granted herein.
IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to
be executed as of the 16th day of October, 2022.
/s/ Laura Shawver